Torrent Pharmaceuticals has announced that it has received an Establishment Inspection Report (EIR) from the USFDA for its manufacturing facility in Pithampur, Madhya Pradesh.
The inspection, conducted between September 16 and September 20, 2024, has been classified under Voluntary Action Indicated (VAI), indicating that the inspection has been successfully closed by the regulatory authority.
This development underscores Torrent Pharma’s compliance with USFDA regulations and is expected to support its operations and reputation in the global pharmaceutical market.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
